{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T21:53:41Z","timestamp":1761947621113},"reference-count":64,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2010,12,1]],"date-time":"2010-12-01T00:00:00Z","timestamp":1291161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,25]],"date-time":"2019-11-25T00:00:00Z","timestamp":1574640000000},"content-version":"vor","delay-in-days":3281,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.1093\/annonc\/mdq122","type":"journal-article","created":{"date-parts":[[2010,3,25]],"date-time":"2010-03-25T03:13:42Z","timestamp":1269486822000},"page":"2305-2315","source":"Crossref","is-referenced-by-count":34,"title":["Bevacizumab in combination with taxanes for the first-line treatment of metastatic breast cancer"],"prefix":"10.1016","volume":"21","author":[{"given":"A.","family":"Chan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.W.","family":"Miles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X.","family":"Pivot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdq122_bb0010","unstructured":"National Comprehensive Cancer Network. NCCN Guidelines 2009 http:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp (9 July 2009, date last accessed)"},{"key":"10.1093\/annonc\/mdq122_bb0015","doi-asserted-by":"crossref","first-page":"ii11","DOI":"10.1093\/annonc\/mdn072","article-title":"Locally recurrent or metastatic breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up","volume":"19","author":"Kataja","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdq122_bb0020","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1093\/annonc\/mdp261","article-title":"Third consensus on medical treatment of metastatic breast cancer","volume":"20","author":"Beslija","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdq122_bb0025","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/sj.bjc.6602680","article-title":"A systematic review of taxane-containing regimens for metastatic breast cancer","volume":"93","author":"Ghersi","year":"2005","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdq122_bb0030","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1200\/JCO.2007.10.8399","article-title":"Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer","volume":"26","author":"Piccart-Gebhart","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq122_bb0035","doi-asserted-by":"crossref","first-page":"5542","DOI":"10.1200\/JCO.2005.02.027","article-title":"Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer","volume":"23","author":"Jones","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq122_bb0040","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1200\/JCO.2007.11.6699","volume":"26","author":"Seidman","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq122_bb0045","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1200\/JCO.2003.08.013","article-title":"Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193)","volume":"21","author":"Sledge","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq122_bb0050","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1200\/JCO.2003.04.040","article-title":"Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial","volume":"21","author":"Nabholtz","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq122_bb0055","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s10549-007-9651-3","article-title":"A phase-III trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer: results of the ERASME 3 study","volume":"109","author":"Cassier","year":"2008","journal-title":"Breast Cancer Res Treat"},{"key":"10.1093\/annonc\/mdq122_bb0060","doi-asserted-by":"crossref","first-page":"3950","DOI":"10.1200\/JCO.2007.11.9362","article-title":"Gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment","volume":"26","author":"Albain","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq122_bb0065","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1200\/JCO.2002.09.002","article-title":"Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results","volume":"20","author":"O'Shaughnessy","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq122_bb0070","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1200\/JCO.2007.15.8485","article-title":"Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer","volume":"27","author":"Chan","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq122_bb0075","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003372.pub2","article-title":"Single agent versus combination chemotherapy for metastatic breast cancer","author":"Carrick","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1093\/annonc\/mdq122_bb0080","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1093\/annonc\/mdn171","article-title":"A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients","volume":"19","author":"Pivot","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdq122_bb0085","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1093\/annonc\/mdn060","article-title":"Phase II multicenter study of larotaxel (XRP9881), a novel taxoid, in patients with metastatic breast cancer who previously received taxane-based therapy","volume":"19","author":"Dieras","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdq122_bb0090","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.1200\/JCO.2006.09.3849","article-title":"Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine","volume":"25","author":"Perez","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq122_bb0095","doi-asserted-by":"crossref","first-page":"7794","DOI":"10.1200\/JCO.2005.04.937","article-title":"Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer","volume":"23","author":"Gradishar","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq122_bb0100","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.1200\/JCO.2008.18.5397","article-title":"Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer","volume":"27","author":"Gradishar","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq122_bb0105","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s10549-007-9591-y","article-title":"Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer","volume":"108","author":"Lee","year":"2008","journal-title":"Breast Cancer Res Treat"},{"key":"10.1093\/annonc\/mdq122_bb0110","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1038\/sj.bjc.6603332","article-title":"Phase II and pharmacological study of oral paclitaxel (Paxoral) plus ciclosporin in anthracycline-pretreated metastatic breast cancer","volume":"95","author":"Helgason","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdq122_bb0115","first-page":"34s","article-title":"Lapatinib (L) with paclitaxel compared to paclitaxel as first-line treatment for patients with metastatic breast cancer: a phase III randomized, double-blind study of 580 patients","volume":"25","author":"di Leo","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq122_bb0120","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdq122_bb0125","doi-asserted-by":"crossref","first-page":"4265","DOI":"10.1200\/JCO.2005.04.173","article-title":"Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group","volume":"23","author":"Marty","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq122_bb0130","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1056\/NEJM197111182852108","article-title":"Tumor angiogenesis: therapeutic implications","volume":"285","author":"Folkman","year":"1971","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdq122_bb0135","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1200\/JCO.2005.06.081","article-title":"Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis","volume":"23","author":"Hicklin","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq122_bb0140","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/nm988","article-title":"Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer","volume":"10","author":"Willett","year":"2004","journal-title":"Nat Med"},{"key":"10.1093\/annonc\/mdq122_bb0145","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0002-9440(10)63273-7","article-title":"Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts","volume":"165","author":"Inai","year":"2004","journal-title":"Am J Pathol"},{"key":"10.1093\/annonc\/mdq122_bb0150","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.ejca.2008.01.005","article-title":"The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer: clinical experience with anti-angiogenic agents, focusing on bevacizumab","volume":"44","author":"Marty","year":"2008","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdq122_bb0155","first-page":"4593","article-title":"Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders","volume":"57","author":"Presta","year":"1997","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdq122_bb0160","unstructured":"Genentech, Inc. US Prescribing Information for Avastin2009http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/125085s0168lbl.pdf (11 March 2010, date last accessed)"},{"key":"10.1093\/annonc\/mdq122_bb0165","unstructured":"F. Hoffmann-La Roche Ltd. Avastin Summary of Product Characteristics2009http:\/\/www.emea.europa.eu\/humandocs\/PDFs\/EPAR\/avastin\/emea-combined-h582en.pdf (11 March 2010, date last accessed)"},{"key":"10.1093\/annonc\/mdq122_bb0170","first-page":"327","article-title":"In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic\/pharmacodynamic relationship","volume":"9","author":"Mendel","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdq122_bb0175","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nbt1068","article-title":"A small molecule-kinase interaction map for clinical kinase inhibitors","volume":"23","author":"Fabian","year":"2005","journal-title":"Nat Biotechnol"},{"key":"10.1093\/annonc\/mdq122_bb0180","first-page":"1843","article-title":"The microtubule-affecting drug paclitaxel has antiangiogenic activity","volume":"2","author":"Belotti","year":"1996","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdq122_bb0185","first-page":"3369","article-title":"The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors","volume":"61","author":"Sweeney","year":"2001","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdq122_bb0190","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1056\/NEJMoa072113","article-title":"Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer","volume":"357","author":"Miller","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdq122_bb0195","doi-asserted-by":"crossref","first-page":"4966","DOI":"10.1200\/JCO.2008.21.6630","article-title":"Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer","volume":"27","author":"Gray","year":"2009","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1093\/annonc\/mdq122_bb0200","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S1359-6349(08)70289-1","article-title":"Bevacizumab in the first-line treatment of metastatic breast cancer","volume":"6","author":"Cameron","year":"2008","journal-title":"Eur J Cancer Suppl"},{"key":"10.1093\/annonc\/mdq122_bb0205","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2008.21.6457","article-title":"Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of HER2-negative metastatic breast cancer","author":"Miles","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq122_bb0210","doi-asserted-by":"crossref","first-page":"42s","DOI":"10.1200\/jco.2009.27.15_suppl.1005","article-title":"RIBBON-1: randomised, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for the first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC)","volume":"27","author":"Robert","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq122_bb0215","doi-asserted-by":"crossref","first-page":"50s","DOI":"10.1200\/jco.2008.26.15_suppl.1036","article-title":"Independent review of E2100 validates progression-free survival (PFS) improvement with the addition of bevacizumab (B) to paclitaxel (P) as initial chemotherapy for metastatic breast cancer (MBC)","volume":"26","author":"Klencke","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq122_bb0220","doi-asserted-by":"crossref","first-page":"1008s","DOI":"10.1200\/jco.2008.26.15_suppl.lba1011","article-title":"Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO","volume":"26","author":"Miles","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq122_bb0225","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S1359-6349(09)70909-7","article-title":"Multinational study (n=2041) of first-line bevacizumab (Bev) plus taxane-based chemotherapy (CT) for locally recurrent or metastatic breast cancer (LR\/mBC): updated results of MO19391","volume":"7","author":"Cortes-Funes","year":"2009","journal-title":"Eur Cancer Suppl"},{"key":"10.1093\/annonc\/mdq122_bb0230","doi-asserted-by":"crossref","first-page":"64s","DOI":"10.1200\/jco.2009.27.15_suppl.1094","article-title":"Clinical benefit of bevacizumab (BV) + first-line docetaxel (D) in elderly patients (pts) with locally-recurrent (LR) or metastatic breast cancer (mBC): AVADO study","volume":"27","author":"Pivot","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq122_bb0235","doi-asserted-by":"crossref","first-page":"48s","DOI":"10.1200\/jco.2009.27.15_suppl.1032","article-title":"Tolerability and efficacy of first-line bevacizumab (B) plus chemotherapy (CT) in elderly patients with advanced breast cancer (aBC): subpopulation analysis of the MO19391 study","volume":"27","author":"Biganzoli","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq122_bb0240","doi-asserted-by":"crossref","first-page":"193s","DOI":"10.1158\/0008-5472.SABCS-2120","article-title":"Triple negative breast cancer: a phase 2, multi-center, open-label, randomized trial of gemcitabine\/carboplatin (G\/C), with or without BSI-201, a PARP inhibitor","volume":"69","author":"O'Shaughnessy","year":"2009","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdq122_bb0245","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1093\/jnci\/dji174","article-title":"Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab","volume":"97","author":"Ince","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdq122_bb0250","doi-asserted-by":"crossref","unstructured":"H Hurwitz J Yi W Ince. The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of k-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer.Presented at the 2008 World Congress on Gastrointestinal Cancer, Barcelona, Spain (Abstr O-035)","DOI":"10.1634\/theoncologist.2008-0213"},{"key":"10.1093\/annonc\/mdq122_bb0255","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1200\/JCO.2005.01.5388","article-title":"Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer","volume":"24","author":"Jubb","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq122_bb0260","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1158\/1078-0432.CCR-07-1154","article-title":"Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab\u2014an Eastern Cooperative Oncology Group Study","volume":"14","author":"Dowlati","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdq122_bb0265","doi-asserted-by":"crossref","first-page":"4672","DOI":"10.1200\/JCO.2008.16.1612","article-title":"Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100","volume":"26","author":"Schneider","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq122_bb0270","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.ccr.2009.01.021","article-title":"Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis","volume":"15","author":"Ebos","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1093\/annonc\/mdq122_bb0275","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.ccr.2009.01.027","article-title":"Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis","volume":"15","author":"Paez-Ribes","year":"2009","journal-title":"Cancer Cell"},{"issue":"Suppl. 3","key":"10.1093\/annonc\/mdq122_bb0280","article-title":"No clinical evidence for increase in tumour malignant potential in patients (pts) with metastatic breast cancer (mBC) treated with bevacizumab (BV) and docetaxel (D) in the phase III AVADO study","volume":"69","author":"Harbeck","year":"2009","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdq122_bb0285","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1159\/000088481","article-title":"Managing patients treated with bevacizumab combination therapy","volume":"69","author":"Gordon","year":"2005","journal-title":"Oncology"},{"key":"10.1093\/annonc\/mdq122_bb0290","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for the treatment of metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdq122_bb0295","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer","volume":"355","author":"Sandler","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdq122_bb0300","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1200\/JCO.2001.19.6.1707","article-title":"Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial","volume":"19","author":"Jassem","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq122_bb0305","first-page":"S28","article-title":"Phase II combined biological therapy targeting the HER2 proto-oncogene and the vascular endothelial growth factor using trastuzumab (T) and bevacizumab (B) as first line treatment of HER2-amplified breast cancer","volume":"100","author":"Pegram","year":"2006","journal-title":"Breast Cancer Res Treat"},{"key":"10.1093\/annonc\/mdq122_bb0310","doi-asserted-by":"crossref","first-page":"370","DOI":"10.3816\/CBC.2008.n.045","article-title":"RiBBON 1 and RiBBON 2: phase III trials of bevacizumab with standard chemotherapy for metastatic breast cancer","volume":"8","author":"O'Shaughnessy","year":"2008","journal-title":"Clin Breast Cancer"},{"issue":"Suppl. 3","key":"10.1093\/annonc\/mdq122_bb0315","article-title":"RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of HER2-negative metastatic breast cancer","volume":"69","author":"Brufsky","year":"2009","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdq122_bb0320","series-title":"Cancer: Principles and Practice of Oncology","first-page":"2865","article-title":"Antiangiogenesis agents","author":"Folkman","year":"2006"},{"issue":"6","key":"10.1093\/annonc\/mdq122_bb0325","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S1359-6349(08)70291-X","article-title":"Future use of bevacizumab and other anti-angiogenic agents in breast cancer","volume":"6","author":"Cameron","year":"2008","journal-title":"Eur J Cancer Suppl"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419392452?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419392452?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/21\/12\/2305\/499426\/mdq122.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T06:11:01Z","timestamp":1685513461000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419392452"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12]]},"references-count":64,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["S0923753419392452"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdq122","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2010,12]]}}}